ArticleBMC cancer2026
Glucose-transporter 1 (GLUT1) as a prognostic biomarker: evidence from 14,966 human tumors across 134 cancer types.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Low E-cadherin expression is associated with poor prognosis in pulmonal adenocarcinoma.Scientific reports · 2026Article
- Glioblastoma Stem Cells and Tumour Microenvironment: Interactions Across Hypoxia, Vasculature and Immune Modulation.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlucose transporter 1 (GLUT1) is a key protein for transmembranous glucose uptake of cells which is often overexpressed in cancer.
methodsTo better comprehend the prevalence and role of GLUT1 expression in different cancer types, a tissue microarray containing 14,966 samples from 134 different tumor entities was analyzed in this study. GLUT1 expression was generally markedly higher in cancer than in corresponding normal tissues.
resultsA total of 122 of 134 tumor categories showed GLUT1 expression in at least 1 case, and 97 tumor categories included at least 1 case with strong GLUT1 staining. The frequency of GLUT1 positivity was particularly high in squamous cell carcinomas of various sites of origin (92.9%-100%), urothelial neoplasms (91.3%-98.7%), and carcinomas of the ovary and the endometrium (up to 100%). Elevated levels of GLUT1 staining were often associated with parameters of cancer aggressiveness. For example, high GLUT1 staining was associated with invasive growth of urothelial carcinomas (p = 0.0003), high grade (p = 0.0075), advanced pT stage (p = 0.025), and shorter survival (p = 0.0031) in clear cell renal cell carcinoma, high grade (p = 0.0500) and distant metastasis (p = 0.011), as well as shorter recurrence free survival (p = 0.0253) in papillary renal cell carcinoma, high grade in invasive breast cancer of no special type (p = 0.0003), advanced pT stage (p = 0.0008), nodal metastasis (p = 0.0007), V1 status (p = 0.004), and L1 status (p = 0.0008) in colorectal adenocarcinoma, and advanced pT stage (p = 0.0459) and MMR deficiency (p = 0.0018) in gastric cancer.
conclusionsIt is concluded, that GLUT1 is highly expressed in a broad range of tumor entities, that it occurs more often in malignant than in benign tumors, and that it is linked to aggressive behavior in many different entities. These findings identify GLUT1 as a critical prognostic cancer marker, which may be clinically useful in many cancer types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.